# FosunAdgenvax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fosunadgenvax

- Industry: Pharmaceuticals
- Headquarters: Chengdu, China
- Website: www.adgenvax.com
- Latest round: Series A (Jun 15, 2017)
- Investors on record: 2

## About

Based in Chengdu, China, and established in 2012, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., trading as FosunAdgenvax focuses on the development, manufacture and marketing of vaccine including pneumococcal, tetanus vaccine and rabies vaccine. In June 2026, FosunAdgenvax raised CNY 968 million in venture funding from Shanghai Fosun Pharmaceutical (Group), Prosperico Ventures, CR Capital, BIO-TOWN Capital, with participation from other investors.

Its products cover pneumococcal vaccines, tetanus toxoids, and other categories. Its independently developed 13-valent pneumococcal vaccine is currently undergoing clinical trial applications, and it also holds a patent for a pneumococcal conjugate vaccine.

The company generates revenue by developing, manufacturing, and selling vaccines, including pneumococcal, tetanus, and rabies vaccines, as well as advancing early-stage vaccine research and clinical development programs.

The funding raised in June 2026 will be used to focus on further expanding its innovative R&D pipeline, accelerating the engineering construction of high-standard production bases, and significantly increasing investment in the end-market promotion and commercialization of its marketed products.

## Funding rounds

- Series A, Jun 15, 2017 — Yuexiu Industrial Investment Funds Management
- Angel, Aug 10, 2016 — Prosperico Ventures

## Investors

- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Angel
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A